Insider Trading April 21, 2026 07:28 PM

Aehr Test Systems Director Scott Gates Disposes $5.66 Million in Shares

Insider sale occurs amid near-term strength in share price, large hyperscale order and recent equity offering

By Priya Menon AEHR
Aehr Test Systems Director Scott Gates Disposes $5.66 Million in Shares
AEHR

Scott Gates, a director at Aehr Test Systems, sold a total of $5,660,000 of common stock on April 21, 2026, per a Securities and Exchange Commission filing. The transactions involved multiple block sales at prices between $91.00 and $95.00 per share. The moves leave Mr. Gates with a direct holding of 52,864 shares, including shares subject to unvested restricted stock units, while certain indirect holdings held by a trust and by his spouse were reduced but remain substantial. These trades take place as the company's shares trade near their 52-week high and after a period of notable operational developments, including a record hyperscale order and a completed at-the-market equity offering.

Key Points

  • Director Scott Gates sold $5.66 million in Aehr common stock at $91.00 to $95.00 per share.
  • Transactions reduced certain indirect holdings while Mr. Gates retains 52,864 directly held shares including unvested restricted stock units.
  • Company activity includes a $60 million at-the-market offering, a record $41 million hyperscale order for AI processor ASIC testing equipment, and Q3 fiscal 2026 revenue of $10.3 million with record bookings of $37.2 million.

Insider transaction details

Aehr Test Systems director Scott Gates sold a total of $5,660,000 worth of the company's common stock on April 21, 2026, according to a recent SEC filing. The disposition consisted of multiple transactions executed at prices ranging from $91.00 to $95.00 per share.

One block sale involved 10,000 shares sold at $91.00 per share. Those shares were held indirectly by a trust. After that sale, the trust's indirect holding stood at 50,686 shares. Separately, a 50,000-share block was sold at $95.00 per share; those shares were held indirectly by Mr. Gates' spouse. Following the sale, the spouse continued to hold 50,000 shares indirectly.

Direct holdings post-sale

Following these transactions, Mr. Gates directly holds 52,864 shares of Aehr Test Systems common stock. That total includes shares that remain subject to unvested restricted stock units.

Share price context

The sales were executed as Aehr Test Systems shares traded at $93.72, a level close to the stock's 52-week high of $99.67. The company’s shares have experienced a steep rise over the past year, recording a total return of 1,077% over that period.

Valuation note

An InvestingPro analysis cited in the filing indicates that the stock currently appears overvalued relative to its Fair Value estimate. The analysis and associated tools referenced include detailed valuation metrics and supplemental guidance on overvalued stocks.

Recent company developments

Operational and capital-markets developments at Aehr Test Systems were reported alongside the insider sale. The company completed a $60 million at-the-market stock offering, generating proceeds through sales of common stock. Separately, Aehr reported receipt of a record $41 million order from a hyperscale customer for AI processor ASICs, described as the largest order in the company’s history. That order encompasses high-power package-level test and burn-in systems, with deliveries scheduled to begin in fiscal 2027.

On the quarterly front, Aehr Test Systems reported Q3 fiscal 2026 revenue of $10.3 million, a figure slightly below the consensus estimate. The company also disclosed record quarterly bookings amounting to $37.2 million.

Analyst commentary and price targets

Two analyst actions accompanying these updates were noted. Freedom Broker raised its price target for Aehr Test Systems to $61 while maintaining a Hold rating, citing strong demand metrics despite a small revenue miss in the third quarter. Lake Street increased its price target to $56 and kept a Buy rating, pointing to strong bookings momentum as a supporting factor.

Takeaway

The disclosed insider sale by a director reduces certain indirect shareholdings while leaving Mr. Gates with a meaningful direct stake that includes unvested restricted stock units. The trades occurred against a backdrop of strong year-over-year share performance, elevated booking activity, a record hyperscale order with deliveries slated for fiscal 2027, and a completed at-the-market equity raise.


Key points

  • Director Scott Gates sold $5,660,000 in Aehr Test Systems stock on April 21, 2026, in transactions priced between $91.00 and $95.00 per share.
  • Post-transaction, Mr. Gates directly holds 52,864 shares, including shares subject to unvested restricted stock units; indirect holdings by a trust and spouse were reduced but remain material.
  • Company developments include a $60 million at-the-market offering, a record $41 million hyperscale order for AI processor ASIC test and burn-in systems with deliveries beginning fiscal 2027, and Q3 fiscal 2026 revenue of $10.3 million with record bookings of $37.2 million.

Risks and uncertainties

  • Valuation risk: Independent analysis cited in the filing indicates the stock appears overvalued relative to a Fair Value estimate, which may affect investor expectations in the semiconductor test equipment sector.
  • Operational and execution timing: The record hyperscale order's deliveries are scheduled to begin in fiscal 2027, creating a timing gap between recognized bookings and revenue realization that could influence near-term performance in the supplier and equipment sectors.
  • Market and capital-raising effects: The completion of a $60 million at-the-market stock offering increased common-stock sales by the company, which may influence share supply and investor perception in capital markets.

Risks

  • InvestingPro analysis indicates the stock appears overvalued relative to its Fair Value estimate - impacts investor sentiment and valuation in the semiconductor equipment sector.
  • Deliveries for the record $41 million hyperscale order begin in fiscal 2027, creating timing and execution uncertainty for revenue recognition in the industrials and semiconductors supply chain.
  • The recent $60 million at-the-market equity offering increased the supply of common stock, which may affect market dynamics and investor perception.

More from Insider Trading

Photronics Executive Sells $212,765 in Stock as Company Posts Better-Than-Expected Q1 Results Apr 21, 2026 Enliven Therapeutics CMO Sells 4,900 Shares in Rule 10b5-1 Transaction Apr 21, 2026 Sionna Therapeutics Director Disposes of $2.47M in Stock Under 10b5-1 Plan Apr 21, 2026 OrbiMed Entities Dispose of $2.47M in Sionna Therapeutics Shares Apr 21, 2026 Planet 13 Operations VP Disposes of 32,500 Shares Worth $4,904 Apr 21, 2026